Home/Filings/4/0001209191-21-053721
4//SEC Filing

Bhatt Elizabeth 4

Accession 0001209191-21-053721

CIK 0001828522other

Filed

Aug 26, 8:00 PM ET

Accepted

Aug 27, 6:43 PM ET

Size

15.4 KB

Accession

0001209191-21-053721

Insider Transaction Report

Form 4
Period: 2021-08-25
Transactions
  • Conversion

    Class A Common Stock

    2021-08-25+9,0479,047 total(indirect: By LLC)
  • Disposition to Issuer

    Class B Common Stock

    2021-08-258,4538,453 total(indirect: By LLC)
    Common Stock (8,453 underlying)
  • Conversion

    Class B Common Stock

    2021-08-259,0470 total(indirect: By LLC)
    Common Stock (9,047 underlying)
Footnotes (3)
  • [F1]On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock.
  • [F2]Represents shares held directly by the Sponsor, of which LWAC D&O LLC is a member.
  • [F3]Pursuant to an agreement by and between the Issuer and Locust Walk Sponsor, LLC (the "Sponsor"), concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.

Issuer

eFFECTOR Therapeutics, Inc.

CIK 0001828522

Entity typeother

Related Parties

1
  • filerCIK 0001748622

Filing Metadata

Form type
4
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 6:43 PM ET
Size
15.4 KB